Rockeby strikes deal with UK's Nucare:
This article was originally published in Clinica
Australia-listed, Singapore-based diagnostics group Rockeby biomed is to see its CanDia5 rapid test for candida distributed in the UK over the next five years by Nucare, a Milton Keynes-based marketing and support organisation for independent chemists and pharmaceutical companies. Under the terms of the agreement, Nucare will have exclusive distribution rights to the test for the first two years, as well as licences to other diagnostic tests produced or sold by Rockeby in the future. The CanDia5, used to detect vulvovaginal candidiasis (vaginal thrush), was recently CE-marked for over-the-counter sales. This will allow NuCare to sell the test for home use, under its own label in pharmacies in both the UK and Ireland.